<scp>TNF</scp>‐alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients

Simone, Clara De; Farina, Marisa; Maiorino, Alessia; Fanali, Caterina; Perino, Francesca; Flamini, A.; Caldarola, Giacomo; Sgambato, Alessandro

doi:10.1111/jdv.13024

Cited by 33 publications

(37 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, presence of the TNF-α -857 C allele predicted a better response to TNF antagonists in psoriasis. Our study supports the reliability of TNF-α polymorphisms in predicting the response to anti-TNF therapy, and suggests that individuals with the TNF-α -308 G, -238 G and -857 C common alleles are better responders to TNF-α blockers than those with minor alleles in autoimmune diseases such as spondyloarthropathy, psoriasis [17] Papamichael et al (2011) [16] Papamichael et al (2011) [16] Vasilopoulos et al (2012) [12] Vasilopoulos et al (2012) [12] De Simone et al (2015) [10] De Simone et al (2015) [10] 0.907 0.907 and Crohn's disease. Although heterogeneity was not identified in this meta-analysis, it is hard to exclude that some does not exist, and therefore there is some uncertainty in the findings if the results from metaanalysis can be applied universally to all of the conditions included in the analysis.…”

Section: Discussionmentioning

confidence: 99%

“…Three studies were excluded due to duplicate data [27], lack of extractable data [28] and data on other polymorphisms [29]. Thus, a total of ten studies met the inclusion criteria [10][11][12][13][14][15][16][17][18]30] (Figure 1). Three of the eligible studies contained data on two [13], three [11] or four different groups [17] therefore these were treated independently.…”

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

“…Pharmacogenomics (Epub ahead of print) future science group Systematic Review Song, Seo, Kim, Choi, Ji & Lee potential contributions of TNF-α polymorphisms on responsiveness to TNF antagonists [10][11][12][13][14][15][16][17][18]. However, these studies have often produced contradictory results.…”

mentioning

confidence: 99%

“…Given the crucial roles played by TNF-α polymorphisms in the pathogenesis of the diseases, many studies have examined the Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis 10.2217/PGS. 15.90…”

mentioning

confidence: 99%

See 3 more Smart Citations

Association Between Tnf-α (-308 A/G, -238 A/G, -857 C/T) Polymorphisms and Responsiveness to Tnf-α Blockers in Spondyloarthropathy, Psoriasis and Crohn’S Disease: A Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Studies Included In the Meta-analysismentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Association Between Tnf-α (-308 A/G, -238 A/G, -857 C/T) Polymorphisms and Responsiveness to Tnf-α Blockers in Spondyloarthropathy, Psoriasis and Crohn’S Disease: A Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…SNPs in TNF promoter were evaluated also by De Simone et al, and rs361525 (-238G allele; p = 0.03) and rs1800629 (-308GG genotype; p = 0.001) were found to be associated with good drug response [48].…”

Section: Pharmacogenetics Of Anti-tnfα Treatmentmentioning

confidence: 99%

Pharmacogenetics of Psoriasis Treatment

Redenšek¹,

Dolžan²

2017

An Interdisciplinary Approach to Psoriasis

View full text Add to dashboard Cite

Psoriasis is a chronic systemic, immune-mediated disorder of unknown aetiology, usually presenting with typical inlammatory skin lesions and/or joint manifestations, but systemic inlammation that may lead to the development of co-morbidities may also be present. First-line therapy encompasses local cutaneous treatment and phototherapy, but with more severe symptoms or systemic course, systemic treatment with methotrexate (MTX), immunosuppressant cyclosporine, retinoid acitretin or biologicals may be used. Treatment response varies between patients in terms of eicacy and/or toxicity, which could, among other reasons, be due to genetic diferences between patients. Approximately 10-30% of patients experience adverse drug reactions with MTX treatment, leading to discontinuation of MTX mostly due to hepatotoxicity. Around 15% of patients experience adverse events when treated with biologicals; however, the most frequent reason for discontinuation is ineicacy or loss of the initially favourable response over time. Ineicacy or occurrence of adverse drug reactions cannot be predicted, so genetic biomarkers of drug response in combination with clinical data could be helpful in treatment planning. Several polymorphic genes have already been associated with treatment outcome, most of them involved in drug metabolism, transport and target pathways. Genetic biomarkers could be helpful in personalized care of psoriasis patients in order to prevent adverse events or predict ineicacy of a certain drug.

show abstract

Extracellular Vesicles in Oncology: Progress and Pitfalls in the Methods of Isolation and Analysis

Lucchetti

Fattorossi

Sgambato

2018

Biotechnology Journal

View full text Add to dashboard Cite

The possibility to study solid tumors through the analysis of extracellular vesicles in biological fluids is one of the most exciting and rapidly advancing field in cancer research. The extracellular vesicles are tiny sacs released in both physiological and pathological conditions and can be used to monitor the evolution of several pathological states, including neoplastic diseases. Indeed, these vesicles carry biological informations and can affect the behavior of recipient cells by transferring proteins, DNA, RNA, and microRNA. In this review the authors analyze the methods to collect biological fluid samples (urine, plasma/serum, and cell supernatant), and to isolate and quantify extracellular vesicles highlighting advantages and drawbacks. Moreover, the authors provide an overview on the adoption and the advantages of the methods (such as digital PCR, next generation sequencing, reverse-phase protein microarrays, flow-cytometry, etc.) most frequently used to analyze the molecular content of extracellular vesicles. Despite the great scientific interest on this topic, there is still a great uncertainty about which is the best method for the collection, isolation, quantification, and molecular evaluation of these vesicles and a standardization is needed. The features of EVs make them ideal candidates for liquid biopsy-based biomarkers. However, the small size of EVs makes their analysis very difficult and requires multiple advanced technologies, being therefore a limitation.

show abstract

TNF‐alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients

Cited by 33 publications

References 18 publications

Association Between Tnf-α (-308 A/G, -238 A/G, -857 C/T) Polymorphisms and Responsiveness to Tnf-α Blockers in Spondyloarthropathy, Psoriasis and Crohn’S Disease: A Meta-Analysis

Association Between Tnf-α (-308 A/G, -238 A/G, -857 C/T) Polymorphisms and Responsiveness to Tnf-α Blockers in Spondyloarthropathy, Psoriasis and Crohn’S Disease: A Meta-Analysis

Pharmacogenetics of Psoriasis Treatment

Extracellular Vesicles in Oncology: Progress and Pitfalls in the Methods of Isolation and Analysis

Contact Info

Product

Resources

About